This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.
This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products.
The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.
The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.